Phase I trial of polyclonal antibodies, developed in Japan by AnGes MG using Vical's DNA vaccine technology, for the treatment of Ebola virus infection

Trial Profile

Phase I trial of polyclonal antibodies, developed in Japan by AnGes MG using Vical's DNA vaccine technology, for the treatment of Ebola virus infection

Planning
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Polyclonal antibodies (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors AnGes MG
  • Most Recent Events

    • 30 Jan 2015 New trial record
    • 14 Jan 2015 AnGes has signed an agreement with Vical for the rights to develop and commercialise this product in Japan, and this trial is expected to be initiated in the first quarter of 2015, according to an AnGes MG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top